(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged All three active substances were previously available in the European Union (EU): abacavir was granted marketing authorisation as Ziagen in 1999, lamivudine was granted marketing authorisation as Epivir in 1996, and zidovudine has been available in the EU since the mid-1980s.